FDA Approves Rapid SARS-CoV-2 Diagnostic Test
The FDA issued Emergency Use Authorization for a point-of-care COVID-19 diagnostic for the Cepheid Xpert Xpress SARS-CoV-2 test. The approval is for use of the test in high- and moderate-complexity CLIA-certified laboratories as well as in certain patient care settings. The company intends to roll-out availability of its point-of-care testing by March 30. Read the FDA announcement.